Could Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD)’s Partnership Create the Next Big Pharma Growth Engine
Two biopharmaceutical companies, Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD), have formed a partnership that highlights the potential for collaboration in modern drug development. Both companies reported their first-quarter earnings in 2026, showcasing significant growth fueled by strategic alliances in oncology and virology.
Merck generated $16.3 billion in total sales, with Keytruda contributing $8.0 billion, while Gilead posted $7.0 billion in revenue, with Biktarvy leading the way. The companies' combined efforts have led to two major milestones: the European Medicines Agency's approval of Trodelvy in combination with Keytruda for a specific form of breast cancer, and the successful Phase 3 trial results of a once-weekly oral HIV treatment.
This partnership positions Merck and Gilead as leaders in their respective therapeutic markets, with the potential to create a significant growth engine in the pharmaceutical industry.
Written by urgent.news from Yahoo Finance's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
